Gujarat Themis Biosyn reported a 17% increase in Q4 revenue compared to the previous year, reaching ₹44.2 Crore with an EBITDA margin of 43.8%. For FY26, the company saw a 10% growth in overall revenue to ₹165.8 Crore and recently secured agreements to acquire 13 Sanofi brands and MicroBiopharm Japan.

Gujarat Themis Biosyn announces a revenue of INR 4.51 crores and a profit of INR 1.09 crores in their latest financial report, showing promising growth for the biotech company.

Gujarat Themis Biosyn has established a new subsidiary, Themis Biosyn Japan, on May 19, 2026. This move marks an expansion into the Japanese pharmaceutical market with an initial capital investment of 10 million yen.

Gujarat Themis Biosyn Ltd will announce its financial results and potentially declare a dividend on May 25, 2026. A trading window will remain closed for 48 hours following the announcement.

Gujarat Themis Biosyn experienced a 7.1% drop today, reaching an intraday low of Rs 344.4 due to broader market weakness, sector underperformance, and a recent downgrade to 'Sell'. This marks the third consecutive loss for the company.

NK Securities purchased approximately 591,000 shares of Gujarat Themis Biosyn, with an average price of ₹367.2 each. This move indicates a potential confidence in the company's growth prospects.

Gujarat Themis Biosyn has agreed to acquire 13 anti-infective branded generics from Sanofi for €158 million. This deal is aimed at expanding GTBL's global reach and is expected to be finalized by December 2026, subject to regulatory approvals.

GTBL has secured a €158M acquisition of Sanofi's pharmaceutical portfolio, expanding its reach in the market, particularly in anti-infective treatments. This move strengthens GTBL's position by increasing their offerings and regulatory influence.